Contract research and manufacturing firm Syngene International just posted its Q4 FY25 numbers, and the market didn't take it well.
Despite an 11 per cent revenue rise, net profit dipped 3 per cent, and more importantly, guidance for FY26 was anything but reassuring . Investors hit the exit button fast, sending the stock down nearly 13 per cent in a single day —its sharpest one-day drop in its history.
So what exactly spooked the Street? And is the Syngene growth story coming off the rails?
Syngene Q4 in focus: Revenue up, profit down
| Metric | Q4 FY25 | YoY change |
|---|---|---|
| Revenue | Rs 1,018 crore | +11 per cent |
| Net profit | Rs 183 crore | -3 per cent |
| EBITDA | Rs 343.6 crore | +8.4 per cent |
| EBITDA margin | 33.8 per cent | ↓ from 34.4 per cent |
On the surface, 11 per cent topline growth looks decent. But the margin pressure and flat profits show the company is spending more to deliver that growth. And in a business like Syngene, which operates on scale and cost efficiency, that's not a great look.
Syngene's FY26 guidance
Here's what management said—and why the market didn't like it:
-
Revenue
is expected to grow in the
early teens
, but this includes a
one-time adjustment
. After backing out large molecule inventory effects, the true growth is more like
mid-single digits
.
-
EBITDA margins
are expected to
decline into the mid-20s
, a meaningful drop from the current 33-34 per cent levels.
- Net profit could fall YoY , according to the CFO.
That's a lot of caution, especially from a company seen as a steady compounder in the pharma outsourcing space.
What's causing the slowdown?
A few reasons:
-
Inventory balancing
in biologics, particularly large molecules, is expected to reduce the contribution from that segment next year.
-
Cost pressures and new investments
—including a recent US facility buy—may compress margins in the near term.
- The CDMO (contract development and manufacturing) industry is facing post-COVID normalisation , where the breakneck demand from the past couple of years is tapering off.
The valuation point
Syngene currently trades at a P/E of 55. Meanwhile, AstraZeneca Pharma commands a far steeper P/E of 234, but it operates in a different corner of the pharma ecosystem, with a focus on patented drugs rather than services.
So, where does that leave Syngene? For a company that just guided for lower profit growth, a 55x multiple feels stretched.
Unless earnings catch up, there's a risk the stock may de-rate—not because the business is broken, but because expectations need a reset.
Value Research Online Ratings
Value Research Stock Rating gives Syngene International an overall rating of 3 stars. The company's specific scores are as follows:
-
Quality Score: 8/10
-
Growth Score: 7/10
-
Valuation Score: 3/10
- Momentum Score: 4/10
- Compare Syngene's margins and ROCE with peers using our Stock Screener
- Get a full snapshot of Syngene's financials, dividends and growth history on its Stock Card
Final take
Yes—Syngene still operates in a high-growth sector. The company has clients like Bristol Myers Squibb, strong capabilities in biologics and chemistry and is now expanding its global manufacturing footprint.
Its acquisition of a biologics plant in the US is a long-term positive. It positions Syngene better in the high-value CDMO market, even if it hurts margins in the short term.
Its long-term growth potential remains, but for now, the stock is priced for a pace it may not deliver in FY26. With a P/E of 55, it's still valued like a growth stock, even though the guidance doesn't scream growth.
Looking for more than just market buzz?
At
Value Research Stock Advisor
, we go beyond trends. As a subscriber, you get access to a carefully curated list of high-conviction stock recommendations, three ready-to-use portfolios (aggressive growth, long-term growth and dividend growth) and timely updates—built on long-term thinking, not just headlines. Whether you are looking to build a solid portfolio or simply make more informed investment decisions, we are here to help you cut through the noise.
Ask Value Research 
New episodes every Friday 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
